trending Market Intelligence /marketintelligence/en/news-insights/trending/bs07oxgvz7k9tieoqzglda2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Regenxbio closes common stock offering


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Regenxbio closes common stock offering

Regenxbio Inc. closed an underwritten public offering of 2,700,000 common shares, priced $65 each.

The Rockville, Md.-based developer of gene therapies raised gross proceeds of about $201.8 million.

Underwriters fully exercised their option to buy 405,000 additional shares at the offering price.

Morgan Stanley, Bank of America Merrill Lynch and Barclays acted as joint book-running managers for the offering, with Raymond James as co-manager.